HALO - HALOZYME THERAPEUTICS, INC.

QQQ $ 462.76 $ -0.41 (-0.09 %)

DIA $ 388.38 $ -0.84 (-0.22 %)

SPY $ 533.54 $ -0.65 (-0.12 %)

TLT $ 91.51 $ -1.71 (-1.83 %)

GLD $ 211.60 $ -7.83 (-3.57 %)

Previous Close

$ 50.85

Open

$ 50.99

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 50.42 - $ 51.88

52 Week Range

$ 32.78 - $ 53.00

Volume

1,821,470

Average Volume

Market Cap

6.55B

Beta (5Y Monthly)

$ 1.03

PE Ratio (TTM)

$ 20.56

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-07-2024	03-31-2024	10-Q
2	02-20-2024	12-31-2023	10-K
3	11-06-2023	09-30-2023	10-Q
4	08-08-2023	06-30-2023	10-Q
5	05-09-2023	03-31-2023	10-Q
6	02-21-2023	12-31-2022	10-K
7	11-08-2022	09-30-2022	10-Q
8	08-09-2022	06-30-2022	10-Q
9	05-10-2022	03-31-2022	10-Q
10	02-22-2022	12-31-2021	10-K
11	11-02-2021	09-30-2021	10-Q
12	08-09-2021	06-30-2021	10-Q
13	05-10-2021	03-31-2021	10-Q
14	02-23-2021	12-31-2020	10-K
15	11-02-2020	09-30-2020	10-Q
16	08-10-2020	06-30-2020	10-Q
17	05-11-2020	03-31-2020	10-Q
18	02-24-2020	12-31-2019	10-K
19	11-12-2019	09-30-2019	10-Q
20	08-06-2019	06-30-2019	10-Q
21	05-07-2019	03-31-2019	10-Q
22	02-21-2019	12-31-2018	10-K
23	11-06-2018	09-30-2018	10-Q
24	08-07-2018	06-30-2018	10-Q
25	05-10-2018	03-31-2018	10-Q
26	02-20-2018	12-31-2017	10-K
27	11-07-2017	09-30-2017	10-Q
28	08-08-2017	06-30-2017	10-Q
29	05-09-2017	03-31-2017	10-Q
30	02-28-2017	12-31-2016	10-K
31	11-07-2016	09-30-2016	10-Q
32	08-09-2016	06-30-2016	10-Q
33	05-09-2016	03-31-2016	10-Q
34	02-29-2016	12-31-2015	10-K
35	11-09-2015	09-30-2015	10-Q
36	08-10-2015	06-30-2015	10-Q
37	05-11-2015	03-31-2015	10-Q
38	03-02-2015	12-31-2014	10-K
39	11-10-2014	09-30-2014	10-Q
40	08-11-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

this-exxon-mobil-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-friday

This Exxon Mobil Analyst Is No Longer Bull...
06/07/2024 13:30:32

Wells Fargo Maintains Overweight on Halozy...
06/07/2024 12:39:57

Wells Fargo analyst Mohit Bansal maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and raises the price target...

HC Wainwright & Co. Maintains Buy on Haloz...
06/07/2024 11:13:35

HC Wainwright & Co. analyst Mitchell Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the pric...

Piper Sandler Downgrades Halozyme Therapeu...
06/07/2024 09:20:03

Piper Sandler analyst Joseph Catanzaro downgrades Halozyme Therapeutics (NASDAQ:HALO) from Overweight to Neutral and raises ...

why-g-iii-apparel-shares-are-trading-lower-by-13-here-are-other-stocks-moving-in-thursdays-mid-day-session

Why G-III Apparel Shares Are Trading Lower...
06/06/2024 17:39:18

halozyme-therapeutics-13-on-thursday-whats-going-on

Halozyme Therapeutics +13% On Thursday: Wh...
06/06/2024 16:34:07

Halozyme Therapeutics surges as it raises FY24 guidance, driven by increased revenue projections and a new European patent for ...

jm-smucker-posts-upbeat-earnings-joins-toro-company-united-natural-foods-semtech-and-other-big-stocks-moving-higher-on-thursday

J.M. Smucker Posts Upbeat Earnings, Joins ...
06/06/2024 14:44:41

Halozyme Therapeutics Increases FY24 Adj. ...
06/06/2024 12:43:23

Halozyme Receives Issuance Of New European...
06/05/2024 20:08:49

Conference Call Scheduled for Thursday, June 6 at 5:30am PT/8:30am ETSAN DIEGO, June 5, 2024 /PRNewswire/ -- Halozyme Therapeut...

A Glimpse Into The Expert Outlook On Haloz...
06/04/2024 12:00:20

HC Wainwright & Co. Reiterates Buy on Halo...
06/04/2024 10:28:31

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $50 ...

HC Wainwright & Co. Reiterates Buy on Halo...
05/22/2024 11:32:26

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $50 ...

Halozyme Discloses That Bristol Myers Squi...
05/21/2024 11:55:38

Halozyme announced that Bristol Myers Squibb was reassigned a Prescription Drug User Fee Act goal date from the U.S. Food and D...

JMP Securities Maintains Market Outperform...
05/08/2024 17:58:25

JMP Securities analyst Jason Butler maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and lowers the pr...

HC Wainwright & Co. Reiterates Buy on Halo...
05/08/2024 11:30:14

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $50 ...

Halozyme Reiterates FY24 Guidance: Sees To...
05/07/2024 20:29:11

Halozyme Therapeutics Q1 2024 Adj EPS $0.7...
05/07/2024 20:24:43

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $0.79 per share which beat the analyst consensus estimate of...

Expert Ratings For Halozyme Therapeutics
05/07/2024 14:00:56

HC Wainwright & Co. Reiterates Buy on Halo...
05/07/2024 10:14:31

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $50 ...

HC Wainwright & Co. Reiterates Buy on Halo...
04/30/2024 10:35:58

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $50 ...